Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine, Oxaliplatin, and Radiotherapy for Esophageal Cancer
NCT00470184Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Nov 2006
- Primary completion
- Oct 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in esophageal cancer, sponsored by Roswell Park Comprehensive Cancer Center. Started Nov 2006; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00470184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00470184.